Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 37 entries
View as:

A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy

Phase: N/A Priority: Normal
NCT ID: NCT01556776 Org: User:
Start: 07/20/12 End: 01/14/21 Due: 01/14/22

Sequential Regimen of Bendamustin [B] Followed by GA101 and Ibrutinib [I] in CLL Patients

Phase: N/A Priority: Normal
NCT ID: NCT02345863 Org: User:
Start: 01/16/15 End: 03/29/19 Due: 03/29/20

Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment with or Without Sonrotoclax for Patients with Richter Transformation

Phase: N/A Priority: Normal
NCT ID: NCT04271956 Org: User:
Start: 02/19/20 End: 08/31/26 Due: 08/31/27

Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Phase: N/A Priority: Normal
NCT ID: NCT04608318 Org: User:
Start: 03/01/21 End: 09/30/27 Due: 09/30/28

Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL)

Phase: N/A Priority: Normal
NCT ID: NCT01186640 Org: User:
Start: 06/30/10 End: 05/31/14 Due: 05/31/15

Methotrexate Followed by Fludarabine in Patients With T-Cell Large Granular Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00278265 Org: User:
Start: 06/30/05 End: 12/31/09 Due: 12/31/10

A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT01558167 Org: User:
Start: 02/28/11 End: 06/30/15 Due: 06/30/16

Alemtuzumab in Treating Patients With Advanced Chronic Lymphocytic Leukemia That Did Not Respond to Previous Fludarabine

Phase: N/A Priority: Normal
NCT ID: NCT00274976 Org: User:
Start: 09/30/02 End: 08/31/09 Due: 08/31/10

Fludarabine or Chlorambucil as First-Line Therapy in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00262795 Org: User:
Start: 09/30/03 End: 10/31/05 Due: 10/31/06

Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00275054 Org: User:
Start: 10/31/05 End: 06/30/15 Due: 06/30/16

Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia

Phase: N/A Priority: Normal
NCT ID: NCT00281983 Org: User:
Start: 06/30/00 End: 07/31/10 Due: 07/31/11

Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL)

Phase: N/A Priority: Normal
NCT ID: NCT00147901 Org: User:
Start: 01/31/05 End: 11/30/11 Due: 11/30/12

Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)

Phase: N/A Priority: Normal
NCT ID: NCT02689141 Org: User:
Start: 02/04/16 End: 02/06/20 Due: 02/06/21

Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00281931 Org: User:
Start: 09/30/99 End: 10/31/06 Due: 10/31/07

Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00278213 Org: User:
Start: 09/30/02 End: 12/31/09 Due: 12/31/10

Fludarabine or Observation in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00262782 Org: User:
Start: 04/30/97 End: 06/30/10 Due: 06/30/11

Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

Phase: N/A Priority: Normal
NCT ID: NCT02950051 Org: User:
Start: 12/13/16 End: 02/29/24 Due: 02/28/25

Cyclophosphamide and Total Body Irradiation in Treating Patients Who Are Undergoing an Autologous Peripheral Stem Cell Transplant For Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00275015 Org: User:
Start: 01/31/98 End: 04/30/12 Due: 04/30/13

Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG)

Phase: N/A Priority: Normal
NCT ID: NCT02445131 Org: User:
Start: 05/28/15 End: 03/09/22 Due: 03/09/23

Combination Chemotherapy With or Without G-CSF in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00416910 Org: User:
Start: 07/31/99 End: 09/30/07 Due: 09/30/08

Bendamustine and Rituximab in Treating Patients With Previously Untreated or Relapsed Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00274989 Org: User:
Start: 11/30/05 End: 03/31/11 Due: 03/31/12

Ibrutinib in Previously Untreated Binet Stage a Chronic Lymphocytic Leukemia with Risk of Disease Progression

Phase: N/A Priority: Normal
NCT ID: NCT02863718 Org: User:
Start: 04/30/14 End: 07/11/22 Due: 07/11/23

Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients with Relapsed/refractory CLL

Phase: N/A Priority: Normal
NCT ID: NCT03787264 Org: User:
Start: 01/14/19 End: 09/26/23 Due: 09/26/24

Fludarabine With or Without Cyclophosphamide in Treating Patients With Advanced Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00276848 Org: User:
Start: 07/31/99 End: 07/31/07 Due: 07/31/08

Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT)

Phase: N/A Priority: Normal
NCT ID: NCT00309881 Org: User:
Start: 04/30/03 End: 03/31/11 Due: 03/31/12